Inner Mongolia Furui Med Sci Asset Resilience Ratio
Inner Mongolia Furui Med Sci asset resilience ratio. Inner Mongolia Furui Med Sci (300049) has an Asset Resilience Ratio of 1.75% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Inner Mongolia Furui Med Sci to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inner Mongolia Furui Med Sci (2010–2025)
Asset resilience ratio of Inner Mongolia Furui Med Sci from 2010 to 2025. This chart shows how Inner Mongolia Furui Med Sci's Asset Resilience Ratio has changed over time. Read Inner Mongolia Furui Med Sci total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inner Mongolia Furui Med Sci's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Inner Mongolia Furui Med Sci asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥60.50 Million | 1.75% |
| Total Liquid Assets | CN¥60.50 Million | 1.75% |
Asset Resilience Insights
- Limited Liquidity: Inner Mongolia Furui Med Sci maintains only 1.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Inner Mongolia Furui Med Sci Industry Peers by Asset Resilience Ratio
Compare Inner Mongolia Furui Med Sci's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Inner Mongolia Furui Med Sci Asset Resilience Ratio by Year (2010–2025)
Inner Mongolia Furui Med Sci asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Inner Mongolia Furui Med Sci.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.43% | CN¥83.62 Million ≈ $12.24 Million |
CN¥3.44 Billion ≈ $503.22 Million |
-2.72pp |
| 2024-12-31 | 5.15% | CN¥157.50 Million ≈ $23.05 Million |
CN¥3.06 Billion ≈ $447.61 Million |
+1.59pp |
| 2023-12-31 | 3.55% | CN¥94.11 Million ≈ $13.77 Million |
CN¥2.65 Billion ≈ $387.41 Million |
-1.84pp |
| 2022-12-31 | 5.40% | CN¥136.20 Million ≈ $19.93 Million |
CN¥2.52 Billion ≈ $369.21 Million |
-0.38pp |
| 2021-12-31 | 5.78% | CN¥145.80 Million ≈ $21.34 Million |
CN¥2.52 Billion ≈ $369.43 Million |
+3.68pp |
| 2020-12-31 | 2.10% | CN¥48.00 Million ≈ $7.02 Million |
CN¥2.29 Billion ≈ $335.18 Million |
-3.95pp |
| 2019-12-31 | 6.05% | CN¥136.10 Million ≈ $19.92 Million |
CN¥2.25 Billion ≈ $329.28 Million |
+1.52pp |
| 2018-12-31 | 4.53% | CN¥96.68 Million ≈ $14.15 Million |
CN¥2.14 Billion ≈ $312.62 Million |
-2.19pp |
| 2017-12-31 | 6.72% | CN¥168.62 Million ≈ $24.67 Million |
CN¥2.51 Billion ≈ $367.37 Million |
+2.24pp |
| 2016-12-31 | 4.48% | CN¥107.80 Million ≈ $15.77 Million |
CN¥2.41 Billion ≈ $352.17 Million |
+0.22pp |
| 2015-12-31 | 4.26% | CN¥87.00 Million ≈ $12.73 Million |
CN¥2.04 Billion ≈ $298.65 Million |
+7.67pp |
| 2014-12-31 | -3.41% | CN¥-45.40 Million ≈ $-6.64 Million |
CN¥1.33 Billion ≈ $194.80 Million |
+0.12pp |
| 2013-12-31 | -3.53% | CN¥-40.29 Million ≈ $-5.90 Million |
CN¥1.14 Billion ≈ $167.08 Million |
-59.95pp |
| 2010-12-31 | 56.42% | CN¥448.91 Million ≈ $65.69 Million |
CN¥795.66 Million ≈ $116.43 Million |
-- |
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liv… Read more